Selexipag not checked
Actelion · JNJ-67896049 · ACT-293987
FollowEvery change as it happens, and a Monday email
Trials
3 active
19 in total · 3 in the EU
What this is
- How it works
- Prostacyclin Receptor Agonist FDA class
- How it’s given
- “Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body…”In the company’s words, NCT05179876 on ClinicalTrials.gov
- Tested for
- Hypertension, Pulmonary (2 trials), Pulmonary Arterial Hypertension
- Main trialPhase 3
- “The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.”In the company’s words, NCT04175600 on ClinicalTrials.gov
- Other names
- JNJ-67896049 · ACT-293987 · Uptravi
Other drugs for Hypertension, Pulmonary
- MosliciguatPulmovant, Inc. · Phase 3
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan / tadalafil FDCActelion · Phase 3
Copies tested against it1
Other companies’ versions, mostly cheaper copies for when the patent ends
- Selexipag Film CoatedHumanis Saglık Anonim Sirketi · NCT07694128, NCT06932198 · finished
Coming up1
- 31 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials19
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 11 Oct 2024 | A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension | |
| Phase 3Recruiting | 31 Jan 2027 | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | |
| Phase 2Active, not recruiting | 28 Mar 2022 | A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension | |
| Phase 4Completed | 10 Feb 2020 | Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. | |
| Phase 4Terminated | 28 Jul 2023 | A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging | |
| Phase 3Completed | 1 Apr 2014 | Selexipag (ACT-293987) in Pulmonary Arterial Hypertension | |
| Phase 3Completed | 29 May 2018 | Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension | |
| Phase 3Completed | 29 Aug 2019 | The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension | |
| Phase 3Completed | 26 Aug 2021 | ACT-293987 in Pulmonary Arterial Hypertension | |
| Phase 3Terminated | 7 Jun 2022 | A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment | |
| Phase 3Completed | 10 Nov 2023 | A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study | |
| Phase 2Completed | 30 Apr 2015 | Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis | |
| Phase 2Terminated | 19 Apr 2023 | A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag | |
| Phase 1Completed | Dec 2012 | Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg | |
| Phase 1Completed | Apr 2015 | Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects | |
| Phase 1Completed | Jun 2016 | Comparison of Two Dose Strengths of Selexipag in Healthy Adults | |
| Phase 1Completed | Jul 2016 | A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects | |
| Phase 1Completed | 10 May 2018 | A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects | |
| Phase 1Completed | 14 Aug 2020 | A Study of Selexipag in Healthy Male Participant |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026